Incyte Genomics and several other companies were also directing their research and development towards cDNA sequencing; and finally, a battle over patents on the BRCA1 and BRCA2 genes, responsible for inherited risks of breast and ovarian cancers, was smoldering between Myriad Genetics in Utah and OncorMed in Maryland, alongside parallel clashes over BRCA2 in the UK and elsewhere (Davies and White 1996; Gold and Carbone 2010; Baldwin and Cook-Deegan 2013; Sherkow and Greely 2015, pp. The gene discussed is BRCA2; the disease is ovarian cancer.